Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of vedolizumab in the patients with inflammatory bowel disease (IBD) requiring surgery

Next Previous
Trial Profile

A study of vedolizumab in the patients with inflammatory bowel disease (IBD) requiring surgery

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 16 May 2017 New trial record
    • 08 May 2017 According to a Takeda Pharmaceutical media release, this trial consisted of 306 ulcerative colitis patients and 436 patients of Crohn's disease.
    • 08 May 2017 According to a Takeda Pharmaceutical media release, results from this trial from the U.S. VICTORY (Vedolizumab for Health OuTComes in InflammatORY Bowel Diseases) consortium was presented at the 2017 Digestive Disease Week (DDW) annual scientific meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top